Enhancement of anti-inflammatory activity of fucoxanthin through encapsulation in alginate/chitosan nanoparticles for potential osteoarthritis treatment
Issued Date
2025-07-01
Resource Type
ISSN
01418130
eISSN
18790003
Scopus ID
2-s2.0-105007154437
Journal Title
International Journal of Biological Macromolecules
Volume
318
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Biological Macromolecules Vol.318 (2025)
Suggested Citation
Sorasitthiyanukarn F.N., Muangnoi C., Haworth I.S., Rojsitthisak P., Rojsitthisak P. Enhancement of anti-inflammatory activity of fucoxanthin through encapsulation in alginate/chitosan nanoparticles for potential osteoarthritis treatment. International Journal of Biological Macromolecules Vol.318 (2025). doi:10.1016/j.ijbiomac.2025.144873 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110608
Title
Enhancement of anti-inflammatory activity of fucoxanthin through encapsulation in alginate/chitosan nanoparticles for potential osteoarthritis treatment
Corresponding Author(s)
Other Contributor(s)
Abstract
This study introduces a novel hydrocolloid-based drug delivery system for enhancing the therapeutic potential of fucoxanthin (FX) through encapsulation in alginate/chitosan nanoparticles (FX-Alg/CS-NPs) for osteoarthritis (OA) treatment. FX-Alg/CS-NPs were fabricated using an oil-in-water (o/w) emulsification and ionotropic gelation technique, yielding highly stable nanoparticles (size: 235 ± 23 nm; zeta potential: 34.4 ± 0.9 mV; encapsulation efficiency: 80.3 ± 1.5 %). This work represents the first evaluation of nanoparticles in an IL-1β-stimulated SW-1353 chondrosarcoma cell model of OA, demonstrating significantly enhanced anti-inflammatory activity compared to free FX. Encapsulation protected FX from enzymatic degradation, improved its stability, and enabled controlled release under physiological and arthritis-relevant conditions. FX-Alg/CS-NPs significantly suppressed key inflammatory mediators, including IL-6, IL-8, MCP-1, ICAM-1, and iNOS, while inhibiting phosphorylation of MAPK signaling components (p38, ERK1/2, JNK1/2), highlighting their mechanistic role in inflammation suppression. Transmission electron microscopy (TEM) imaging confirmed efficient cellular uptake of FX-Alg/CS-NPs without cytotoxic effects. This study advances the field of nanomedicine by presenting a stable FX delivery system, offering a promising therapeutic strategy for OA treatment and paving the way for the preclinical and clinical translation of hydrocolloid-based nanoformulations.